1JNJ trade ideas
Johnson & Johnson shares Buy IdeaJNJ shares Buy Idea @ Weekly Demand Zone (114.70 - 110.71)
Buy Limit: 114.70
Stop Loss: 109.07
Take Profit: 128.32
JOHNSON & JOHNSONI see prices going lower, possibly close to the 120.00 Region.
We could see a potential bounce on this region, however prices could of course go a lot lower and reverse up to highs of 136.00.
Let's Wait And See !
Blood Sugar Makes You HighJohnson & Johnson has been honored for its dedication to people, innovation and the health of people around the world! Therefore, A Model Company.
Economically, a new blockbuster is emerging! The company has received a takeover bid for its blood glucose control business. The investment company Platinum Equity is willing to pay 2.1 billion US-Dollar for this division of the US pharmaceutical company.
Our recognition - blood sugar makes you high!
What has happened lately?
Johnson & Johnson hit the list of the best jobs Glassdoor's 2018. The company was named to Glassdoor’s 2018 List of best places to work, based solely on the positive feedback from its employees.
Additionally, Johnson & Johnson named a 2017 Fortune's Most Admired Company.
However, last year's financial results were rather disappointing. Johnson & Johnson's net income for 2017 was $1.3 billion, compared to $16.5 billion a year earlier.
A contributing cause for the lousy results was the tax payments of $13.6 billion required in the fourth quarter of last year.
At the same time, the company's worldwide sales for the full-year 2017 grew. According to Johnson & Johnson's 2017 Full Year Earnings Report, the company announced $76.5 billion in sales in 2017, with growth reported in all three sectors: Consumer, Medical Devices and Pharmaceuticals. This is an increase of 6.3% versus 2016.
What to expect from Johnson&Johnson this year?
In the annual forecast for 2018, the company indicated the expected revenue of $80.6 billion to $81.4 billion. The company also announced adjusted earnings guidance for full-year 2018 of $8.00 to $8.20 per share compared to recorded $7.30 in 2017.
Afterwards, as mentioned earlier, there is a lucrative takeover bid of $2.1 billion for its blood glucose control business.
What do the technical analysis methods I use say?
Oscillator: The RSI is around 53 - the rise above the 50 mark is reached!
Price Indicator: The stock price is below the SMA200 ($136). This resistance is now to crack!
Trend indicator: The MACD is currently in the positive zone.
As it is seen in the chart, after the publication of the financial figures at the beginning of the year, there was a veritable consolidation. This could have currently found a bottom.
The question arises: "Is a stable countermovement started now?"
Now the SMA 200 (blue line at around $136) has to be overcome, after this the way to the first target (visible in the chart as a green line) is probably largely free.
The risk management tool used here is the own-developed “Traffic Signals System” (TSS) and is preferably used in analyzes by Ritschy Dobetsberger.
The black line in the chart: the starting price of the idea is 133.80 US-Dollar.
The red line in the chart: the stop loss is lying at 125.00 US-Dollar.
The green line in the chart: First goal in the idea at around 148 US-Dollar.
Disclosure:
"The trading ideas published here are neither to be understood as a recommendation nor as an offer or an invitation to buy or sell financial instruments and should not be understood as such.
You must also assume that the author holds the recommended position in his portfolio and benefits from the implementation of his trading ideas."
Long on JNJWait until the candle closes above the trendline and then buy in antisipation that JNJ will go up in price.
JNJ looks like it will have another leg downJNJ is currently forming a bear flag, which if confirms to the down side, projects to drop into the box (around $117.50). Lots of resistance overhead, all the moving averages and the .236 fib at 133. The more time JNJ spends below 133, the more likely it is to break down. Trade carefully
JNJLong JNJ via short put spread.
Short Mar16 125/130 put spread for $1.10.
POP: 69%
BPR: $390
Max loss: $390
Max Win: $110
Target: 50-60% of credit received
Stop loss: Price at $127 or $350ish loss.
short 130 put: 37 delta
long 125 put: 15 delta
If this starts to get really ugly, I may pull off before $127.
JNJ wait for a break of supportJNJ made a bearish move after earnings.
There was a recent period of consolidation / pause.
Opportunity to look for break-down of support to make a bearish trade
LONG ON JOHNSON & JOHNSON?JOHNSON & JOHNSON.
We're currently in a bearish trend, could we go back to the upside?
I believe that we could see some real bullish movement if prices takes out our prior higher high sitting near the 134.00 Region, up to highs of at least 142.00.
TP: 142.00/146.00/148.00
Sector: Healthcare. Pharamaceuticals.
Vol: 1.544M
EPS: 0.47
Market Cap: 351.585B
P/E: 338.94
Div Yield: 2.57%
JNJ: another fallen giantJNJ is yet another giant trading under the 200SMA.
Even though we had a strong earnings beat last week JNJ was not protected from the dip.
When the inevitable bottom is formed, I will be looking at these large caps under the 200 for bargain buys.
Hard to say what the near term status is for JNJ, following that of the market.
I would be looking for buys in the $122 range.
JNJ Long at WK and MN Demand zoneJNJ touched WK Demand nested inside of MN demand, long option trade triggered.
JNJ Road Ahead20171017 - Product Pipeline
"apalutamide (ARN-509) - Prostate cancer pre-metastatic castration-resistant" - Phase III
20171221 - U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
Apalutamide is an investigational, next-generation oral androgen receptor inhibitor that inhibits the action of androgen in prostate cancer cells, and prevents binding of androgen to the androgen receptor, and translocation of the androgen receptor to the nucleus of the cancer cell.
20180118 - with Pfizer in hot pursuit, JNJ loses a critical patent fight as it scrambles for a new prostate cancer drug OK
If J&J loses this battle, it still has a late-stage drug in front of the FDA — apalutamide, or ARN-509 — it’s hoping can protect the big revenue stream it gets from Zytiga (abiraterone), an oral drug that has helped revolutionize prostate cancer treatment over the last 5 years.
J&J won a priority review of apalutamide for nonmetastatic castration resistant prostate cancer, an early designation. And it’s fielding Phase III data that is slated to be revealed at the ASCO Genitourinary Cancers Symposium on February 8. The accelerated PDUFA date is in April.
Looking at the support levels for JNJ to bounce atI drew two support levels where JNJ could bounce off of. I'll be watching how the candles form over the next few days. For my daily trading log, you can view them here: www.youtube.com
JNJ put saleJNJ had a massive move down on their earnings. This is one of the largest candles I can even find on the chart for JNJ. As is approached the 50EMA I was looking for Bull Put Spread or Put Sale premium. Because of dividends being at the end of February and the 200 SMA down around 134. It seems like a no brainer.
JOHNSON & JOHNSON PULL BACK TO SUPPORT OF ITS TRIANGLE-LONGJ&J STOCK, AFTER BREAKS UP A TRIANGLE PATTERN IS PULLING BACK TO SUPPORT AT 137.25, WHICH GIVE A GOOD OPPORTUNITY TO ENTER .
I AM EXPECTING THE STOCK HOLDS AT SUPPORT AND BOUNCE. THE INITIAL TARGET COULD BE 145, WHICH IS THE 200% OF FIBONACCI EXTENSION OF THE PREVIOUS LOW.
HOWEVER, THE TRIANGLE CALL FOR A LONG TERM TARGET OF 151-152 MINIMUM.
IF THE STOCK PRICE BREAKS SUPPORT DOWN FOR A GOOD MARGIN, THE STOP LOSS IS SET UP AT 134.
THIS ANALYSIS IS FOR EDUCATION PURPOSES.
GOOD LUCK!!!!
www.tradingview.com
JNJ Stochastic Divergence Falling Wedge Breakout
JNJ has stochastic divergence (1h) at the breakout point of a falling edge.
Buy: 138.34
Target: 140.27 - 141.83 (1.40% - 2.52%)
